STOCK TITAN

INVO Bioscience to Participate in the Lytham Partners Winter 2021 Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

INVO Bioscience (NASDAQ: INVO), a medical device company specializing in infertility treatments, will participate in the Lytham Partners Winter 2021 Investor Conference from December 13-16, 2021. A webcasted Fireside Chat is scheduled for 11:00am ET on December 13, discussing company insights and strategies. Virtual one-on-one meetings with management are available. The INVOcell®, their flagship product, is an innovative in vivo culture system aimed at providing accessible and affordable fertility solutions. For more details, visit their website.

Positive
  • None.
Negative
  • None.

SARASOTA, Fla., Dec. 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the company will be participating in a webcasted Fireside Chat discussing the business and conducting 1x1 virtual investor meetings.

The webcasted Fireside Chat will be available for viewing at 11:00am ET on Monday, December 13, 2021 at https://wsw.com/webcast/lytham3/invo/2053560. The webcast will also be available for replay following the event.

To arrange a 1x1 meeting with management, please contact Lytham Partners at 1x1@lythampartners.com  or register at www.lythampartners.com/winter2021invreg.

About INVO Bioscience

We are a medical device company focused on creating simplified, affordable treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. For more information, please visit https://www.invobioscience.com/

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-to-participate-in-the-lytham-partners-winter-2021-investor-conference-301442446.html

SOURCE INVO Bioscience, Inc.

FAQ

What is the date of INVO Bioscience's participation in the Lytham Partners Winter 2021 Investor Conference?

INVO Bioscience will participate in the Lytham Partners Winter 2021 Investor Conference from December 13-16, 2021.

When will the Fireside Chat by INVO Bioscience be held?

The webcasted Fireside Chat by INVO Bioscience will be held at 11:00am ET on December 13, 2021.

How can investors arrange a one-on-one meeting with INVO Bioscience management?

Investors can arrange a one-on-one meeting with INVO Bioscience management by contacting Lytham Partners at 1x1@lythampartners.com or registering online.

What is the INVOcell® and its significance in infertility treatment?

The INVOcell® is a patented medical device used for in vivo incubation of eggs and sperm, offering an innovative alternative to traditional IVF and aimed at making fertility treatments more accessible.

Where can I watch the INVO Bioscience Fireside Chat replay?

The replay of the INVO Bioscience Fireside Chat will be available on the same webcast link after the event.

INVO BioScience,INC

NASDAQ:INVO

INVO Rankings

INVO Latest News

INVO Stock Data

3.25M
3.91M
0.63%
3.1%
0.05%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SARASOTA